A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
← catalyst calendarNCT06612268 · readout in 373 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
408estimated
Sites
175
Countries
Australia, Belgium, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-17 | actual | When the study began enrolling |
| Primary completion | 2027-08-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-12 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Sickle Cell Disease
Interventions
- Drug: Etavopivat
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of adjudicated Vaso-occlusive crisis (VOC) events with a medical contact
measured Baseline (week 0) to week 52
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed